These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26771611)

  • 1. Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation.
    Brunt EM
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26771611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology of nonalcoholic steatohepatitis.
    Brunt EM
    Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Sumida Y; Nakajima A; Itoh Y
    World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health.
    Fierbinteanu-Braticevici C; Sinescu C; Moldoveanu A; Petrisor A; Diaconu S; Cretoiu D; Braticevici B
    Cell Biol Toxicol; 2017 Feb; 33(1):5-14. PubMed ID: 27680752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
    Gunn NT; Shiffman ML
    Clin Liver Dis; 2018 Feb; 22(1):109-119. PubMed ID: 29128050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 11. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 20. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.